

Electronic Supplementary Information

Substituent-oriented C-N bond formation *via* N-H insertion or Wolff rearrangement of 5-aryl-1*H*-pyrazoles and diazo compounds


Youpeng Zuo, Xinwei He,* Yi Ning, Qiang Tang, Mengqing Xie, Wangcheng Hu,
Yongjia Shang*

Key Laboratory of Functional Molecular Solids, Ministry of Education, Anhui Laboratory of Molecule-Based Materials (State Key Laboratory Cultivation Base), College of Chemistry and Materials Science, Anhui Normal University, Wuhu 241002, P.R. China

Table of content

Table S1. Optimization of the Wolff-rearrangement reactions condition-----	S1
Experimental section-----	S2
Characterization Data of Compounds 3 and 7 -----	S3-S10
Characterization Data of Compounds 5 , 8 and 11ab -----	S10-S13
Characterization Data of Compounds 10aa-10ac -----	S13-S14
X-Ray Crystallography structures of Compounds 3nc , 5na and 10ac -----	S15
Copies of ¹ H, ¹⁹ F, and ¹³ C NMR Spectra for all compounds-----	S16-S80

Table S1. Optimization of the Wolff-rearrangement Reaction Conditions.^a



entry	solvent	temp (°C)	yield ^b (%)
1	toluene	reflux	46
2	MeOH	reflux	trace
3	DMF	90	trace
4	DMSO	90	trace
5	DCM	reflux	42
6	DCE	reflux	81
7	MeCN	reflux	65
8	DCE	rt	12
9	DCE	50	46
10	DCE	70	64
11 ^c	DCE	reflux	38
12 ^d	DCE	reflux	81

^a Reaction conditions: 5-phenyl-1*H*-pyrazole **1a** (0.5 mmol), 2-diazo-1-phenylbutane-1,3-dione **4b** (0.5 mmol), solvent (3 mL) for 3 h. ^b Isolated yields. ^c Reaction time for 1 h, ^d Reaction time for 6 h.

Experimental

General experimental method

Unless otherwise specified, all reagents and starting materials were purchased from commercial sources and used as received, and the solvents were purified and dried using standard procedures. The chromatography solvents were technical grade and distilled prior to use. The substrates of cyclic 2-diazo-1,3-diketones **1** and pyrazoles **2** are known, and synthesized by reported methods.^{20,21} Flash chromatography was performed using 200-300 mesh silica gel with the indicated solvent system according to standard techniques. The ¹H and ¹³C NMR data were recorded on 300, 500 MHz NMR spectrometers, unless otherwise specified. Chemical shifts (δ) in parts per million are reported relative to the residual signals of chloroform (7.26 ppm for ¹H and 77.16 ppm for ¹³C), and all ¹³C NMR were recorded with proton broadband decoupling and indicated as ¹³C{¹H}NMR. Multiplicities are described as s (singlet), d (doublet), t (triplet), q (quartet), or m (multiplet), and the coupling constants (J) are reported in Hertz. HRMS analysis with a quadrupole time-of-flight mass spectrometer yielded ion mass/charge (m/z) ratios in atomic mass units. IR spectra were measured as dry films (KBr), and the peaks are reported in terms of wave number (cm⁻¹). The melting points were measured using SGWX-4 melting point apparatus.

General procedure for the synthesis of the **3 or **7**.** A mixture of 5-aryl-1*H*-pyrazoles **1** (0.5 mmol) or 4,5,6,7-tetrahydro-1*H*-indazole **6a** (0.5 mmol), cyclic 2-diazo-1,3-diketones **2** (0.5 mmol), and CuTc (0.05 mmol) in DCE (3 mL) was heated to reflux in an oil bath for 6 h. After the reaction was complete (as determined using TLC), the reaction mixture was cooled to room temperature, extracted with CH₂Cl₂ (3 × 10 mL), and washed with brine. The organic layers were combined, dried over Na₂SO₄, filtered, and then evaporated under vacuum. The residue was purified using flash column chromatography with a silica gel (200-300 mesh), using ethyl acetate and petroleum ether (1:8, v/v) as the elution solvent to give desired product **3** or **7**.

General procedure for the synthesis **5 or **8** or **11ab**.** A mixture of 5-aryl-1*H*-pyrazoles **1** (0.5 mmol) or 4,5,6,7-tetrahydro-1*H*-indazole **6a** (0.5 mmol) or 1*H*-pyrazole **6b** (0.5 mmol) or 4-methyl-1*H*-indazole **7** (0.5 mmol), and noncyclic diazo compounds **4** (0.5 mmol) in DCE (3 mL) was heated to reflux in an oil bath for 3 h. After the reaction was complete (as determined using TLC), the reaction mixture was cooled to room temperature, extracted with CH₂Cl₂ (3 × 10 mL), and washed with brine. The organic layers were combined, dried over Na₂SO₄, filtered, and then evaporated under vacuum. The residue was purified using flash column chromatography with a silica gel (200-300 mesh), using ethyl acetate and petroleum ether (1:8, v/v) as the elution solvent to give desired product **5**, **8** or **11ab**.

General procedure for the synthesis **10.** A mixture of 4-methyl-1*H*-indazole **9** (0.5 mmol), cyclic 2-diazo-1,3-diketones **2** (0.5 mmol), and silver carbonate (0.05 mmol) in DCE (3 mL) was heated to reflux in an oil bath for 6 h. After the reaction was complete (as determined using TLC), the reaction mixture was cooled to room temperature, extracted with CH₂Cl₂ (3 × 10 mL), and washed with brine. The organic layers were combined, dried over Na₂SO₄, filtered, and then evaporated under vacuum. The residue was purified using flash column chromatography with a silica gel (200-300 mesh), using ethyl acetate and petroleum ether (1:8, v/v) as the elution solvent to give desired products **10aa-10ac**.

Characterization Data of Compounds 3 and 7

3-Hydroxy-5,5-dimethyl-2-(3-phenyl-1*H*-pyrazol-1-yl)cyclohex-2-en-1-one (3aa). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 83% yield (117 mg, 0.42 mmol); mp 126-127 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.76 (s, 1H), 7.78 (d, *J* = 7.2 Hz, 2H), 7.46-7.36 (m, 3H), 6.69 (d, *J* = 2.4 Hz, 1H), 2.54 (s, 4H), 1.15 (s, 6H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.0, 150.6, 135.0, 133.9, 129.4, 128.3, 126.0, 117.4, 103.4, 47.0, 32.3, 28.6; IR (KBr) ν 3157, 2976, 2357, 1667, 1610, 1498, 1387, 1264, 1218, 1102, 1083, 996, 835, 775 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₈H₂₀N₂O₂ + H]⁺ 283.1441, found 283.1445.

3-Hydroxy-5,5-dimethyl-2-[3-(*p*-tolyl)-1*H*-pyrazol-1-yl]cyclohex-2-en-1-one (3ba). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 83% yield (123 mg, 0.42 mmol); mp 100-101 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.77 (s, 1H), 7.67 (d, *J* = 8.1 Hz, 2H), 7.24 (d, *J* = 8.1 Hz, 2H), 6.64 (s, 1H), 2.54 (s, 4H), 2.39 (s, 3H), 1.56(s, 6H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 181.8, 150.6, 137.6, 134.8, 131.1, 130.0, 125.9, 117.2, 103.1, 47.1, 32.2, 28.6, 21.6; IR (KBr) ν 3149, 2972, 2402, 1689, 1670, 1587, 1459, 1348, 1247, 1198, 1121, 1079, 1005, 917, 875, 786 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₈H₂₀N₂O₂ + H]⁺ 297.1598, found 297.1597.

3-Hydroxy-2-[3-(4-methoxyphenyl)-1*H*-pyrazol-1-yl]-5,5-dimethylcyclohex-2-en-1-one (3ca). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 82% yield (128 mg, 0.41 mmol); mp 112-113 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.85 (d, *J* = 2.4 Hz, 1H), 7.87 (d, *J* = 7.8 Hz, 2H), 7.68 (d, *J* = 7.8 Hz, 2H), 6.73 (d, *J* = 2.4 Hz, 1H), 3.85 (s, 3H), 2.55 (s, 4H), 1.17 (s, 6H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 181.8, 159.7, 150.3, 134.8, 128.8, 127.3, 126.5, 117.2, 114.8, 114.5, 102.8, 55.9, 47.1, 32.3, 28.6; IR (KBr) ν 3165, 2966, 2362, 2335, 1651, 1614, 1557, 1536, 1449, 1385, 1322, 1218, 1070, 838, 778, 684 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₈H₂₀N₂O₃ + H]⁺ 313.1547, found 313.1550.

2-[3-(4-Chlorophenyl)-1*H*-pyrazol-1-yl]-3-hydroxy-5,5-dimethylcyclohex-2-en-1-one (3da). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (128 mg, 0.41 mmol); mp 123-124 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.84 (d, *J* = 2.1 Hz, 1H), 7.69 (d, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 6.64 (d, *J* = 2.1 Hz, 1H), 2.54 (s, 4H), 1.16 (s, 6H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.3, 149.7, 135.4, 133.0, 132.7, 129.5, 127.7, 117.5, 103.6, 47.0, 32.3, 28.6; IR (KBr) ν 3112, 2894, 1810, 1674, 1648, 1573, 1543, 1473, 1362, 1231, 1134, 1087, 1057, 967, 835, 755 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₇H₁₇ClN₂O₂ + H]⁺ 317.1051, found 317.1052.

3-Hydroxy-5,5-dimethyl-2-{3-[4-(trifluoromethyl)phenyl]-1*H*-pyrazol-1-yl}cyclohex-2-en-1-one (3ea). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 58 % yield (101 mg, 0.29 mmol); mp 96-97 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.85 (d, *J* = 2.1 Hz, 1H), 7.87 (d, *J* = 7.8 Hz, 2H), 7.68 (d, *J* = 7.8 Hz, 2H), 6.73 (d, ⁴*J* = 2.1 Hz, 1H), 2.55 (s, 4H), 1.17 (s, 6H); δ 187.1, 154.2, 142.8, 140.5, 140.3, 133.2 (q, ²*J*_{C-F} = 31.5 Hz), 131.2, 131.1, 130.0 (q, ¹*J*_{C-F} = 270.1 Hz), 122.3, 108.9, 51.7, 37.1, 33.4; ¹⁹F NMR (470 MHz, CDCl₃) δ -62.6; IR (KBr) ν 3167, 3048, 2534, 2415, 1858, 1689, 1634, 1599, 1547, 1531, 1474, 1428, 1316, 1208, 1120, 925, 810, 719 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₈H₁₇F₃N₂O₂ + H]⁺ 351.1315, found 351.1320.

2-(3-([1,1'-Biphenyl]-4-yl)-1*H*-pyrazol-1-yl)-3-hydroxy-5,5-dimethylcyclohex-2-en-1-one

(3fa). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 92 % yield (165 mg, 0.46 mmol); mp 149-150 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.85 (s, 1H), 7.85 (d, J = 7.8 Hz, 2H), 7.65 (t, J = 9.0 Hz, 4H), 7.46 (t, J = 7.5 Hz, 2H), 7.38 (d, J = 7.2 Hz, 1H), 6.71 (d, J = 1.8 Hz, 1H), 2.55 (s, 4H), 1.17 (s, 6H); ¹³C NMR (125 MHz, DMSO-d₆) δ 182.0, 150.3, 140.5, 139.8, 135.1, 133.1, 129.8, 128.3, 127.7, 127.3, 126.5, 117.4, 103.5, 47.0, 32.3, 28.6; IR (KBr) ν 3148, 3032, 2506, 2412, 1810, 1654, 1620, 1548, 1532, 1506, 1449, 1436, 1318, 1209, 1172, 914, 836, 724 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₂₃H₂₂N₂O₂ + H]⁺ 359.1754, found 359.1759.

3-Hydroxy-5,5-dimethyl-2-(3-(*m*-tolyl)-1*H*-pyrazol-1-yl)cyclohex-2-en-1-one (3ga). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 81 % yield (119 mg, 0.41 mmol); mp 89-90 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.79 (s, 1H), 7.57-7.61 (m, 2H), 7.32 (t, J = 7.5 Hz, 1H), 7.18 (d, J = 7.5 Hz, 1H), 6.66 (s, 1H), 2.54 (s, 4H), 2.41(s, 3H), 1.16 (s, 6H); ¹³C NMR (125 MHz, DMSO-d₆) δ 182.0, 150.6, 138.5, 134.9, 133.8, 129.3, 129.0, 126.5, 123.2, 117.3, 103.3, 47.0, 32.3, 28.6, 21.9; IR (KBr) ν 3147, 3028, 2516, 2434, 1811, 1630, 1624, 1540, 1520, 1508, 1428, 1416, 1306, 1218, 1129, 938, 824, 797 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₁₈H₂₀N₂O₂ + H]⁺ 297.1598, found 297.1563.

2-(3-(3-Bromophenyl)-1*H*-pyrazol-1-yl)-3-hydroxy-5,5-dimethylcyclohex-2-en-1-one (3ha). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 82 % yield (147 mg, 0.41 mmol); mp 85-86 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.41 (s, 1H), 7.89 (s, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 6.65 (s, 1H), 2.54 (s, 4H), 1.16 (s, 6H); ¹³C NMR (125 MHz, DMSO-d₆) δ 182.5, 149.4, 136.5, 135.5, 131.7, 130.9, 128.3, 124.9, 122.9, 117.5, 103.8, 47.0, 32.3, 28.6; IR (KBr) ν 3159, 3049, 2537, 2436, 1825, 1641, 1625, 1531, 1516, 1538, 1448, 1433, 1315, 1215, 1137, 930, 859, 748, 672 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₁₇H₁₇BrN₂O₂ + H]⁺ 361.0546, found 361.0543.

2-(3-(2-Chlorophenyl)-1*H*-pyrazol-1-yl)-3-hydroxy-5,5-dimethylcyclohex-2-en-1-one (3ia). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (134 mg, 0.43 mmol); mp 96-97 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.88 (d, J = 2.4 Hz, 1H), 7.68-7.65 (m, 1H), 7.50-7.47 (m, 1H), 7.35-7.29 (m, 2H), 6.91 (d, J = 2.4 Hz, 1H), 2.54 (s, 4H), 1.16 (s, 6H); ¹³C NMR (125 MHz, DMSO-d₆) δ 181.6, 147.6, 133.8, 132.0, 131.2, 130.9, 130.8, 129.6, 127.7, 116.7, 106.5, 46.6, 31.9, 28.2; IR (KBr) ν 3167, 3042, 2515, 2440, 1812, 1614, 1630, 1518, 1503, 1498, 1458, 1413, 1375, 1265, 1187, 991, 876, 748, 513 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₁₇H₁₇ClN₂O₂ + H]⁺ 317.1051, found 317.1055.

3-Hydroxy-5-methyl-2-(3-phenyl-1*H*-pyrazol-1-yl)cyclohex-2-en-1-one (3ab). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (114 mg, 0.43 mmol); mp 84-85 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.83 (s, 1H), 7.73 (d, J = 6.9 Hz, 2H), 7.43-7.35 (m, 3H), 6.66 (s, 1H), 2.71-2.66 (m, 2H), 2.40-2.36 (m, 3H), 1.14 (s, 3H); ¹³C NMR (125 MHz, DMSO-d₆) δ 182.8, 150.6, 135.0, 133.9, 129.5, 128.3, 125.9, 117.9, 103.3, 41.4, 28.1, 21.3; IR (KBr) ν 3174, 3029, 2563, 2427, 1828, 1664, 1632, 1536, 1516, 1499, 1448, 1409, 1336, 1209, 1118, 937, 873, 749, 519 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₁₆H₁₆N₂O₂ + H]⁺ 269.1285, found 269.1286.

3-Hydroxy-2-(3-(4-methoxyphenyl)-1*H*-pyrazol-1-yl)-5-methylcyclohex-2-en-1-one (3cb).

This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (127 mg, 0.43 mmol); mp 82-83 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.77 (s, 1H), 7.70 (d, J = 8.4 Hz, 2H), 6.96 (d, J = 8.1 Hz, 2H), 6.59 (s, 1H), 3.85 (s, 3H), 2.71-2.68 (m, 2H), 2.43-2.36 (m, 3H), 1.13 (d, J = 5.1 Hz, 3H); ¹³C NMR (125 MHz, DMSO-d₆) δ 182.6, 159.6, 150.3, 134.7, 127.3, 126.5, 117.8, 114.8, 102.8, 55.9, 41.5, 28.0, 21.3; IR (KBr) ν 3137, 3021, 2542, 2424, 1836, 1681, 1672, 1563, 1554, 1454, 1449, 1381, 1236, 1218, 927, 871, 772, 649 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₁₇H₁₈N₂O₃ + H]⁺ 299.1441, found 299.1443.

2-(3-(4-Fluorophenyl)-1*H*-pyrazol-1-yl)-3-hydroxy-5-methylcyclohex-2-en-1-one (3kb).

This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 88 % yield (126 mg, 0.44 mmol); mp 100-101 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.81 (s, 1H), 7.75-7.70 (m, 2H), 7.14-7.09 (m, 2H), 6.61 (d, J = 2.4 Hz, 1H), 2.71-2.67 (m, 2H), 2.44-2.36 (m, 3H), 1.14 (d, J = 5.4 Hz, 3H); ¹³C NMR (125 MHz, DMSO-d₆) δ 182.1, 162.5 (q, d, ¹J_{C-F} = 242.3 Hz), 149.9, 135.2, 130.7 (d, ⁴J_{C-F} = 2.5 Hz), 127.9 (d, ³J_{C-F} = 8.0 Hz), 117.4, 116.3 (d, ²J_{C-F} = 21.4 Hz), 103.3, 47.0, 32.3, 28.6; ¹⁹F NMR (470 MHz, CDCl₃) δ -112.9; IR (KBr) ν 3188, 2956, 2876, 2365, 1647, 1614, 1493, 1416, 1382, 1258, 1208, 1073, 1046, 1016, 889, 758, 590 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₁₆H₁₅FN₂O₂ + H]⁺ 287.1190, found 287.1189.

2-(3-(4-Chlorophenyl)-1*H*-pyrazol-1-yl)-3-hydroxy-5-methylcyclohex-2-en-1-one (3db).

This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 89 % yield (134 mg, 0.43 mmol); mp 111-112 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.74 (s, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 2.4 Hz, 1H), 2.73-2.68 (m, 2H), 2.44-2.37 (m, 3H), 1.13 (d, J = 6.0 Hz, 3H); ¹³C NMR (125 MHz, DMSO-d₆) δ 182.9, 149.6, 135.3, 133.0, 132.7, 129.5, 127.6, 118.1, 103.6, 41.4, 28.1, 21.3; IR (KBr) ν 3164, 2930, 2856, 2330, 1630, 1624, 1427, 1406, 1316, 1240, 1248, 1021, 1003, 872, 740, 674 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₁₆H₁₅ClN₂O₂ + H]⁺ 303.0895, found 303.0893.

2-(3-(3-Bromophenyl)-1*H*-pyrazol-1-yl)-3-hydroxy-5-methylcyclohex-2-en-1-one (3hb).

This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 86 % yield (149 mg, 0.43 mmol); mp 83-84 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.81 (d, J = 2.4 Hz, 1H), 7.88 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 6.65 (d, J = 2.4 Hz, 1H), 2.72-2.67 (m, 2H), 2.44-2.36 (m, 3H), 1.14 (d, J = 5.7 Hz, 3H); ¹³C NMR (125 MHz, DMSO-d₆) δ 182.9, 149.3, 136.5, 135.4, 131.7, 130.9, 128.3, 124.8, 122.9, 118.1, 103.8, 41.3, 28.1, 21.3; IR (KBr) ν 3187, 2956, 2830, 2379, 1663, 1624, 1518, 1414, 1407, 1327, 1243, 1201, 1029, 1003, 948, 832, 748, 578 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₁₆H₁₅BrN₂O₂ + H]⁺ 347.0390, found 347.0391.

2-(3-(2,4-Dimethylphenyl)-1*H*-pyrazol-1-yl)-3-hydroxy-5-methylcyclohex-2-en-1-one (3mb).

This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 87 % yield (129 mg, 0.44 mmol); mp 77-78 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.84 (d, J = 2.4 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.10-7.06 (m, 2H), 6.51 (d, J = 2.4 Hz, 1H), 2.70-2.66 (m, 2H), 2.46 (s, 3H), 2.39-2.36 (m, 6H), 1.13 (d, J = 5.4 Hz, 3H); ¹³C NMR (125 MHz, DMSO-d₆) δ 182.1, 150.4, 137.5, 135.8, 133.5, 132.4, 130.3, 129.5, 127.3, 117.3, 105.8, 41.5, 28.0, 22.0, 21.5, 21.2; IR (KBr) ν 3188, 2964, 2849, 2336, 1645, 1663, 1579, 1468, 1448, 1382, 1229, 1203, 1121, 1097, 948, 876, 768, 676 cm⁻¹; HRMS (APCI-TOF) m/z: [M + H]⁺ calcd for [C₁₈H₂₀N₂O₂ + H]⁺ 297.1598, found 297.1597.

5-Hydroxy-4-(3-phenyl-1*H*-pyrazol-1-yl)-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3ac**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 83 % yield (137 mg, 0.42 mmol); mp 90-91 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.83 (s, 1H), 7.78 (d, *J* = 7.2 Hz, 2H), 7.47-7.28 (m, 7H), 6.70 (s, *J* = 2.4 Hz, 1H), 3.57-3.44 (m, 1H), 2.94-2.91 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.5, 150.7, 143.8, 135.0, 134.0, 129.5, 125.4, 128.3, 127.8, 127.7, 125.9, 118.1, 103.4, 40.7, 38.4; IR (KBr) ν 3174, 2897, 2469, 2403, 1874, 1651, 1634, 1542, 1524, 1442, 1379, 1374, 1215, 1070, 827, 718, 675 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₁H₁₈N₂O₂ + H]⁺ 331.1441, found 331.1440.

5-Hydroxy-4-(3-(*p*-tolyl)-1*H*-pyrazol-1-yl)-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3bc**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (146 mg, 0.43 mmol); mp 151-152 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.81 (s, 1H), 7.67 (d, *J* = 8.1 Hz, 2H), 7.39-7.35 (m, 2H), 7.30-7.23 (m, 5H), 6.66 (d, *J* = 2.4 Hz, 1H), 3.54-3.44 (m, 1H), 3.93-2.91 (m, 4H), 2.39 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.3, 150.7, 143.8, 137.6, 134.8, 131.2, 130.1, 129.4, 127.8, 125.9, 118.0, 103.2, 40.7, 38.2, 21.6; IR (KBr) ν 3168, 2896, 2502, 2494, 1836, 1681, 1674, 1667, 1549, 1526, 1534, 1442, 1381, 1374, 1215, 1193, 927, 737, 594 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₂H₂₀N₂O₂ + H]⁺ 345.1598, found 345.1602.

5-Hydroxy-4-(3-(4-methoxyphenyl)-1*H*-pyrazol-1-yl)-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3cc**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 86% yield (154 mg, 0.43 mmol); mp 150-151 °C; ¹H NMR (300MHz, CDCl₃) δ 8.82 (s, 1H), 7.70 (d, *J* = 8.7 Hz, 2H), 7.40-7.26 (m, 5H), 6.97 (d, *J* = 8.7 Hz, 2H), 6.61 (d, *J* = 2.7 Hz, 1H), 3.85 (s, 3H), 3.54-3.43 (m, 1H), 2.93-2.90 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.2, 159.7, 150.5, 143.8, 134.7, 129.4, 127.8, 127.6, 127.3, 126.6, 117.9, 114.9, 102.9, 55.9, 40.8, 38.4; IR (KBr) ν 3154, 2836, 2520, 2434, 1812, 1675, 1677, 1636, 1579, 1549, 1542, 1435, 1336, 1309, 1294, 1173, 997, 749, 694 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₂H₂₀N₂O₃ + H]⁺ 361.1547, found 361.1544.

4-(3-(4-Chlorophenyl)-1*H*-pyrazol-1-yl)-5-hydroxy-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3dc**):** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 86% yield (157 mg, 0.43 mmol); mp 156-157 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.86 (d, *J* = 2.1 Hz, 1H), 7.70 (d, *J* = 8.4 Hz, 2H), 7.42-7.36 (m, 3H), 7.31-7.26 (m, 4H), 6.67 (d, *J* = 2.4 Hz, 1H), 3.54-5.44 (m, 1H), 2.94-2.91 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.6, 149.8, 143.8, 135.3, 133.0, 132.7, 129.5, 129.4, 127.8, 127.6, 118.2, 103.7, 40.7, 38.4; IR (KBr) ν 3179, 2963, 2881, 2372, 1664, 1670, 1549, 1498, 1428, 1372, 1259, 1236, 1179, 1075, 937, 876, 768 cm⁻¹; HRMS (APCI-TOF) calcd for [C₂₁H₁₇ClN₂O₂ + H]⁺ 365.1051, found 365.1053.

4-(3-(4-Bromophenyl)-1*H*-pyrazol-1-yl)-5-hydroxy-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3nc**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 87 % yield (177 mg, 0.44 mmol); mp 175-176 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.82 (s, 1H), 7.64 (d, *J* = 8.4 Hz, 2H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.40-7.35 (m, 2H), 7.30-7.26 (m, 3H), 6.68 (d, *J* = 2.7 Hz, 1H), 3.55-3.44 (m, 1H), 2.94-2.91 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.6, 149.8, 143.8, 135.3, 133.4, 132.4, 129.4, 129.0, 127.8, 127.7, 121.2, 118.2, 103.7, 40.6, 38.4; IR (KBr) ν 3184, 2976, 2849, 2314, 1687, 1679, 1548, 1494, 1400, 1382, 1378, 1279, 1179, 937, 876, 597 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₁H₁₇BrN₂O₂ + H]⁺ 409.0546, found 409.0546.

4-(3-([1,1'-Biphenyl]-4-yl)-1*H*-pyrazol-1-yl)-5-hydroxy-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3fc). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 93% yield (189 mg, 0.47 mmol); mp 174-175 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.84 (s, 1H), 7.85 (d, *J* = 8.1 Hz, 2H), 7.69-7.62 (m, 4H), 7.47 (t, *J* = 7.5 Hz, 2H), 7.40-7.35 (m, 3H), 7.31-7.29 (m, 3H), 6.74 (d, *J* = 2.4 Hz, 1H), 3.53-3.48 (m, 1H), 2.95-2.93 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.5, 150.4, 143.8, 140.5, 139.8, 135.1, 133.2, 129.8, 129.4, 128.3, 127.8, 127.7, 127.3, 126.5, 118.1, 103.6, 40.7, 38.4; IR (KBr) ν 3182, 2850, 2583, 2498, 1851, 1689, 1649, 1638, 1587, 1565, 1518, 1436, 1370, 1348, 1276, 1150, 983, 747, 675 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₇H₂₂N₂O₂ + H]⁺ 407.1754, found 407.1758.

4-(3-Bromophenyl)-1*H*-pyrazol-1-yl)-5-hydroxy-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3hc). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 86% yield (175 mg, 0.43 mmol); mp 142-143 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.85 (s, 1H), 7.90 (s, 1H), 7.69 (d, *J* = 6.9 Hz, 1H), 7.49 (d, *J* = 6.6 Hz, 1H), 7.38-7.26 (m, 6H), 6.68 (s, 1H), 3.52-3.47 (m, 1H), 2.94-2.92 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.3, 149.1, 143.2, 136.2, 135.0, 131.5, 130.5, 129.0, 128.0, 127.4, 127.3, 124.5, 122.6, 117.9, 103.5, 40.4, 38.0; IR (KBr) ν 3183, 2848, 2580, 2489, 1815, 1698, 1649, 1631, 1548, 1525, 1511, 1463, 1384, 1307, 1276, 1142, 938, 774, 689, 574 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₁H₁₇BrN₂O₂ + H]⁺ 409.0546, found 409.0548.

4-(3-(2-Chlorophenyl)-1*H*-pyrazol-1-yl)-5-hydroxy-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3ic). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85% yield (155 mg, 0.43 mmol); mp 125-126 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.89 (d, *J* = 2.4 Hz, 1H), 7.68-7.65 (m, 1H), 7.51-7.48 (m, 1H), 7.36-7.31 (m, 4H), 7.26-7.21 (m, 3H), 6.83 (d, *J* = 2.7 Hz, 1H), 3.53-3.42 (m, 1H), 2.93-2.87 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.2, 148.1, 142.7, 134.1, 132.4, 132.2, 131.6, 131.2, 129.9, 129.7, 129.3, 128.1, 117.8, 107.0, 40.6, 37.7; IR (KBr) ν 3197, 2875, 2497, 2472, 1872, 1674, 1660, 1536, 1472, 1416, 1379, 1248, 1232, 1197, 1037, 927, 842, 748 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₁H₁₇ClN₂O₂ + H]⁺ 365.1051, found 365.1047.

4'-Chloro-5-hydroxy-4-(3-(*p*-tolyl)-1*H*-pyrazol-1-yl)-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3bd). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 86% yield (162 mg, 0.43 mmol); mp 165-166 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.82 (s, 1H), 7.66 (d, *J* = 8.1 Hz, 2H), 7.34 (d, *J* = 8.1 Hz, 2H), 7.26-7.20 (m, 4H), 6.66 (d, *J* = 2.4 Hz, 1H), 3.50-3.41 (m, 1H), 2.90-2.87 (m, 4H), 2.39 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.2, 150.7, 142.8, 137.6, 134.8, 132.2, 130.0, 129.8, 129.3, 125.9, 118.0, 103.2, 40.7, 37.7, 21.6; IR (KBr) ν 3163, 2856, 2463, 2428, 1832, 1644, 1596, 1572, 1463, 1397, 1284, 1223, 1179, 1073, 972, 824, 784 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₂H₁₉ClN₂O₂ + H]⁺ 379.1208, found 379.1211.

4'-Chloro-4-(3-(4-fluorophenyl)-1*H*-pyrazol-1-yl)-5-hydroxy-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3kd). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 89 % yield (170 mg, 0.45 mmol); mp 148-149 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.84 (s, 1H), 7.73 (m, 2H), 7.36-7.31 (m, 2H), 7.24-7.19 (m, 2H), 7.16-7.11 (m, 2H), 6.62 (s, 1H), 3.60-3.34 (m, 1H), 2.90-2.88 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.3, 162.6 (d, ¹J_{C-F} = 242.5 Hz), 150.0, 142.7, 135.1, 132.2, 130.7(d, ⁴J_{C-F} = 2.5 Hz), 129.1, 129.3, 127.9 (d, ³J_{C-F} = 7.9 Hz), 118.1, 116.4 (d, ²J_{C-F} = 21.3 Hz), 103.4, 40.7, 37.8; ¹⁹F NMR (470 MHz, CDCl₃) δ -112.7; IR (KBr) ν 3174, 2869, 2454, 2448, 1872, 1656, 1572, 1569, 1493, 1378,

1279, 1273, 1197, 1167, 927, 842, 737, 634 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₂H₁₉FClN₂O₂ + H]⁺ 383.0957, found 383.0962.

4-(3-(4-Bromophenyl)-1*H*-pyrazol-1-yl)-4'-chloro-5-hydroxy-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3nd). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 89 % yield (197 mg, 0.45 mmol); mp 181-182 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.84 (s, 1H), 7.63 (m, 2H), 7.56 (d, *J* = 8.4 Hz, 2H), 7.35 (d, *J* = 8.4 Hz, 2H), 7.23 (d, *J* = 8.4 Hz, 2H), 6.66 (m, 1H), 3.55-3.38 (m, 1H), 2.90-2.87 (m, 4H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.1, 149.5, 142.4, 134.9, 133.0, 132.0, 131.8, 129.4, 128.9, 127.6, 120.9, 117.8, 103.3, 40.4, 37.4; IR (KBr) *v* 3172, 2896, 2488, 2445, 1862, 1672, 1593, 1569, 1556, 1487, 1374, 1237, 1179, 1170, 972, 824, 773, 534 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₂H₁₉BrClN₂O₂ + H]⁺ 443.0156, found 443.0159.

4'-Chloro-5-hydroxy-4-(3-(*m*-tolyl)-1*H*-pyrazol-1-yl)-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3gd). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (161 mg, 0.43 mmol); mp 125-126 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.82 (s, 1H), 7.57 (d, *J* = 6.6 Hz, 2H), 7.35-7.30 (m, 3H), 7.23-7.18 (m, 3H), 6.68 (s, 1H), 3.52-3.42 (m, 1H), 2.90-2.87 (m, 4H), 2.41 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.3, 150.8, 142.8, 138.5, 134.9, 133.9, 132.5, 129.8, 129.4, 129.3, 129.0, 126.5, 123.1, 118.1, 103.4, 40.7, 37.8, 21.9; IR (KBr) *v* 3179, 2785, 2479, 2427, 1827, 1647, 1606, 1596, 1442, 1436, 1319, 1298, 1202, 1147, 1057, 946, 748, 549 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₂H₁₉ClN₂O₂ + H]⁺ 379.1208, found 379.1210.

4'-Chloro-4-(3-(2,4-dimethylphenyl)-1*H*-pyrazol-1-yl)-5-hydroxy-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one (3md). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 87% yield (170 mg, 0.44 mmol); mp 169-170 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.87 (s, 1H), 7.44 (d, *J* = 7.8 Hz, 1H), 7.34 (d, *J* = 8.1 Hz, 2H), 7.22 (d, *J* = 8.1 Hz, 2H), 7.11-7.07 (m, 2H), 6.55 (s, 1H), 3.47-3.43 (m, 1H), 2.89-2.86 (m, 4H), 2.47 (s, 3H), 2.37 (s, 3H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 181.4, 150.3, 142.4, 137.1, 135.4, 133.2, 132.0, 131.8, 130.0, 129.4, 129.1, 128.9, 126.9, 117.2, 105.6, 40.4, 37.3, 21.7, 21.1; IR (KBr) *v* 3169, 2799, 2579, 2545, 1772, 1762, 1649, 1596, 1556, 1549, 1407, 1347, 1273, 1207, 1174, 1037, 924, 774, 681 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₂₃H₂₁ClN₂O₂ + H]⁺ 393.1364, found 393.1363.

3-Hydroxy-2-(3-(*p*-tolyl)-1*H*-pyrazol-1-yl)cyclohex-2-en-1-one (3be). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:4) to afford a white solid in 77% yield (103 mg, 0.39 mmol); mp 125-126 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.82 (s, 1H), 7.66 (d, *J* = 7.8 Hz, 2H), 7.24 (d, *J* = 7.8 Hz, 2H), 6.64 (d, *J* = 2.4 Hz, 1H), 2.67 (t, *J* = 6.3 Hz, 4H), 2.39 (s, 3H), 2.05 (t, *J* = 6.3 Hz, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 180.4, 147.7, 143.7, 138.4, 132.7, 129.5, 128.6, 125.7, 115.0, 101.9, 33.9, 21.3, 20.0; IR (KBr) *v* 3197, 2875, 2469, 2464, 1856, 1614, 1636, 1518, 1440, 1421, 1373, 1294, 1242, 1167, 1021, 927, 848, 764, 673 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₆H₁₆N₂O₂ + H]⁺ 269.1285, found 269.1288.

3-Hydroxy-2-(3-(4-methoxyphenyl)-1*H*-pyrazol-1-yl)cyclohex-2-en-1-one (3ce). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:4) to afford a white solid in 78 % yield (111 mg, 0.39 mmol); mp 68-69 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.76 (s, 1H), 7.69 (d, *J* = 8.1 Hz, 2H), 6.96 (d, *J* = 8.1 Hz, 2H), 6.58 (s, 1H), 3.84 (s, 3H), 2.66 (m, 4H), 2.05 (m, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 183.2, 159.6, 150.4, 134.7, 127.2, 126.6, 118.2, 114.8, 102.7, 55.9, 33.6, 20.6; IR (KBr) *v* 3176, 2846, 2672, 2554, 1842, 1800, 1649, 1569,

1565, 1549, 1470, 1408, 1327, 1249, 1174, 1048, 974, 687 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₆H₁₆N₂O₃ + H]⁺ 285.1234, found 285.1232.

2-(3-(4-Fluorophenyl)-1*H*-pyrazol-1-yl)-3-hydroxycyclohex-2-en-1-one (3ke). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:4) to afford a white solid in 79 % yield (107 mg, 0.40 mmol); mp 83-84 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.78 (s, 1H), 7.75-7.70 (m, 2H), 7.15-7.09 (m, 2H), 6.61 (s, 1H), 2.67 (t, *J* = 6.3 Hz, 4H), 2.10-2.01 (m, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 183.5, 162.5 (d, ¹J_{C-F} = 242.2 Hz), 149.8, 135.2, 130.7 (d, ⁴J_{C-F} = 2.5 Hz), 127.9 (d, ³J_{C-F} = 8.0 Hz), 118.4, 116.3 (d, ²J_{C-F} = 21.3 Hz), 103.3, 33.5, 20.6; ¹⁹F NMR (470 MHz, CDCl₃) δ -112.9; IR (KBr) *v* 3142, 2832, 2642, 2520, 1863, 1836, 1654, 1587, 1536, 1530, 1428, 1408, 1349, 1232, 1148, 1074, 987, 674 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₅H₁₃FN₂O₂ + H]⁺ 273.1034, found 273.1033.

2-(3-(4-Bromophenyl)-1*H*-pyrazol-1-yl)-3-hydroxycyclohex-2-en-1-one (3ne). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:4) to afford a white solid in 80 % yield (133 mg, 0.40 mmol); mp 123-124 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.78 (s, 1H), 7.60-7.56 (m, 4H), 6.64 (s, 1H), 2.83 (m, 4H), 2.19-1.97 (m, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 183.5, 149.7, 135.3, 133.4, 132.4, 127.9, 121.2, 118.4, 103.5, 33.5, 20.6; IR (KBr) *v* 3199, 2767, 2554, 2572, 1726, 1769, 1672, 1596, 1565, 1507, 1474, 1328, 1221, 1204, 1171, 1021, 824, 628, 611 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₅H₁₃BrN₂O₂ + H]⁺ 333.0233, found 333.0230.

2-(3-(2,4-Dimethylphenyl)-1*H*-pyrazol-1-yl)-3-hydroxycyclohex-2-en-1-one (3me). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:4) to afford a white solid in 78 % yield (110 mg, 0.39 mmol); mp 75-76 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.81 (d, *J* = 2.4 Hz, 1H), 7.43 (d, *J* = 7.8 Hz, 1H), 7.10-7.06 (m, 2H), 6.52 (d, *J* = 2.4 Hz, 1H), 2.66 (t, *J* = 6.3 Hz, 4H), 2.46 (s, 3H), 2.36 (s, 3H), 2.05 (t, *J* = 6.3 Hz, 2H); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 182.7, 150.4, 137.5, 135.8, 133.6, 132.4, 130.3, 129.5, 127.3, 117.6, 105.8, 33.7, 22.0, 21.5, 20.5; IR (KBr) *v* 3167, 2754, 2572, 2526, 1772, 1769, 1696, 1565, 1506, 1481, 1428, 1321, 1204, 1113, 1011, 879, 682 cm⁻¹; HRMS (APCI-TOF) *m/z*: [M + H]⁺ calcd for [C₁₇H₁₈N₂O₂ + H]⁺ 283.1441, found 283.1445.

3-Hydroxy-5,5-dimethyl-2-(4,5,6,7-tetrahydro-2*H*-indazol-2-yl)cyclohex-2-en-1-one (7aa). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 76 % yield (99 mg, 0.38 mmol); mp 112-113 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.37 (s, 1H), 2.68 (t, *J* = 6.3 Hz, 2H), 2.58 (t, *J* = 6.3 Hz, 2H), 2.51-2.47 (m, 4H), 1.84-1.76 (m, 4H), 1.12 (s, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 179.3, 145.6, 128.7, 115.5, 48.1, 31.9, 28.5, 23.6, 23.4, 23.1, 20.7; IR (KBr) *v* 3187, 2887, 1898, 1657, 1684, 1579, 1543, 1510, 1443, 1265, 1121, 954, 873 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₅H₂₀N₂O₂ + H]⁺ 261.1598, found 261.1595.

3-Hydroxy-5-methyl-2-(4,5,6,7-tetrahydro-2*H*-indazol-2-yl)cyclohex-2-en-1-one (7ab). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 72 % yield (88 mg, 0.36 mmol); mp 105-106 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.39 (s, 1H), 2.69-2.55 (m, 6H), 2.83-2.31 (m, 3H), 1.82-1.75 (m, 4H), 1.10 (d, *J* = 5.4 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 180.2, 145.6, 128.9, 115.6, 42.4, 28.0, 23.5, 23.4, 23.1, 21.1, 20.6; IR (KBr) *v* 3198, 2851, 2805, 1859, 1797, 1685, 1628, 1587, 1563, 1486, 1357, 1213, 1194, 1023, 989, 847 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₄H₁₈N₂O₂ + H]⁺ 247.1441, found 247.1448.

5-Hydroxy-4-(4,5,6,7-tetrahydro-2*H*-indazol-2-yl)-1,6-dihydro-[1,1'-biphenyl]-3(2*H*)-one

(7ac). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 63 % yield (97 mg, 0.31 mmol); mp 141-142 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.45 (s, 1H), 7.38-7.26 (m, 5H), 3.49-3.41 (m, 1H), 2.91-2.85 (m, 4H), 2.67 (t, *J* = 5. 7 Hz, 2H), 2.59 (t, *J* = 5.7 Hz, 2H), 1.84-1.77 (m, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 179.0, 145.2, 142.1, 128.8, 128.3, 127.1, 126.6, 115.2, 114.7, 41.0, 38.0, 23.2, 23.0, 22.7, 20.3; IR (KBr) ν 3198, 2883, 1836, 1789, 1684, 1654, 1611, 1593, 1564, 1486, 1358, 1309, 1248, 865, 786 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₉H₂₀N₂O₂ + H]⁺ 309.1598, found 309.1594.

Characterization Data of Compounds 5, 8 and 11ab

2-Methyl-1-(3-phenyl-1*H*-pyrazol-1-yl)butane-1,3-dione (5aa). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 76 % yield (92 mg, 0.38 mmol); mp 65-66 °C; ¹H NMR (300MHz, CDCl₃) δ 8.28 (d, *J* = 2.7 Hz, 1H), 7.83 (d, *J* = 6.3 Hz, 2H), 7.44 (m, 3H), 6.79 (d, *J* = 2.7 Hz, 1H), 4.80 (q, *J* = 7.2 Hz, 1H), 2.40 (s, 3H), 1.52 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (75MHz, CDCl₃) δ 204.0, 169.0, 155.6, 153.4, 131.5, 129.7, 129.3, 128.8, 126.2, 107.9, 52.2, 29.0, 12.7; IR (KBr) ν 3150, 2379, 2354, 1649, 1627, 1539, 1520, 1459, 1431, 1380, 1356, 1282, 1174, 768, 697 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₄H₁₄N₂O₂ + H]⁺ 243.1128, found 243.1133.

2-Methyl-1-(3-(*p*-tolyl)-1*H*-pyrazol-1-yl)butane-1,3-dione (5ba). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 80 % yield (102 mg, 0.40 mmol); mp 56-57 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.27 (d, *J* = 1.8 Hz, 1H), 7.63 (d, *J* = 7.2 Hz, 2H), 7.33 (t, *J* = 7.2 Hz, 1H), 7.22 (d, *J* = 7.5 Hz, 1H), 6.78 (d, *J* = 1.8 Hz, 1H), 4.82 (q, *J* = 7.2 Hz, 1H), 2.42 (s, 3H), 2.40 (s, 3H), 1.52 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 204.1, 169.1, 155.7, 139.5, 129.6, 129.5, 128.7, 126.1, 125.6, 107.8, 52.2, 29.0, 21.4, 12.7; IR (KBr) ν 3163, 2354, 2336, 1628, 1645, 1559, 1559, 1469, 1408, 1380, 1316, 1174, 778, 547 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₅H₁₆N₂O₂ + H]⁺ 257.1285, found 257.1286.

1-(3-([1,1'-Biphenyl]-4-yl)-1*H*-pyrazol-1-yl)-2-methylbutane-1,3-dione (5fa). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (135 mg, 0.43 mmol); mp 115-116 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.31 (s, 1H), 7.90 (d, *J* = 8.1 Hz, 2H), 7.69-7.62 (m, 4H), 7.47 (t, *J* = 7.2 Hz, 2H), 7.39 (d, *J* = 7.2 Hz, 1H), 6.83 (s, 1H), 4.82 (q, *J* = 7.2 Hz, 1H), 2.42 (s, 3H), 1.53 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 204.0, 169.0, 155.3, 142.1, 140.3, 130.4, 129.8, 128.9, 127.7, 127.5, 127.0, 126.7, 107.9, 52.2, 29.0, 12.7; IR (KBr) ν 3159, 2779, 1849, 1697, 1634, 1625, 1593, 1548, 1495, 1413, 1356, 1308, 1228, 1147, 786, 679 cm⁻¹; HRMS (APCI-TOF) calcd for [C₂₀H₁₈N₂O₂ + H]⁺ 319.1441, found 319.1442.

1-(3-(4-Bromophenyl)-1*H*-pyrazol-1-yl)-2-methylbutane-1,3-dione (5na). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 87 % yield (139 mg, 0.44 mmol); mp 86-87°C; ¹H NMR (300 MHz, CDCl₃) δ 8.29 (d, *J* = 2.7 Hz, 1H), 7.69 (d, *J* = 8.7 Hz, 2H), 7.57 (d, *J* = 8.7 Hz, 2H), 6.76 (d, *J* = 2.7 Hz, 1H), 4.78 (q, *J* = 7.2 Hz, 1H), 2.39 (s, 3H), 1.52 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 203.9, 168.9, 154.6, 132.0, 130.5, 129.9, 127.7, 123.5, 107.7, 52.2, 28.9, 12.7; IR (KBr) ν 3148, 2797, 1856, 1687, 1643, 1635, 1575, 1568, 1459, 1431, 1365, 1282, 1174, 768, 668 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₄H₁₃BrN₂O₂ + H]⁺ 321.0233, found 321.0230.

2-Methyl-1-(3-(4-(trifluoromethyl)phenyl)-1*H*-pyrazol-1-yl)butane-1,3-dione (5ea). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford

a white solid in 86 % yield (139 mg, 0.44 mmol); mp 86-87 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.32 (d, $J = 2.4$ Hz, 1H), 7.93 (d, $J = 8.1$ Hz, 2H), 7.70 (d, $J = 8.1$ Hz, 2H), 6.83 (d, $J = 2.4$ Hz, 1H), 4.80 (q, $J = 7.2$ Hz, 1H), 2.40 (s, 3H), 1.54 (d, $J = 7.2$ Hz, 3H); ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 206.0, 169.8, 154.0, 135.9, 131.5, 130.3 (q, $^2J_{\text{C-F}} = 31.9$ Hz), 127.5, 126.5, 126.5, 125.0 (q, $^1J_{\text{C-F}} = 270.4$ Hz), 109.2, 52.7, 29.7, 13.1; ^{19}F NMR (470 MHz, CDCl_3) δ -62.7; IR (KBr) ν 3148, 2899, 1823, 1696, 1670, 1616, 1558, 1473, 1240, 1197, 1046; 948, 857 cm^{-1} ; HRMS (APCI-TOF) calcd for $[\text{C}_{15}\text{H}_{13}\text{F}_3\text{N}_2\text{O}_2 + \text{H}]^+$ 311.1002, found 311.1004.

2-Methyl-1-(3-(4-nitrophenyl)-1*H*-pyrazol-1-yl)butane-1,3-dione (5la). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (122 mg, 0.43 mmol); mp 99-100 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.35-8.29 (m, 3H), 7.99 (d, $J = 8.7$ Hz, 2H), 6.87 (d, $J = 2.7$ Hz, 1H), 4.80 (q, $J = 7.2$ Hz, 1H), 2.41 (s, 3H), 1.55 (d, $J = 7.2$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 203.7, 168.9, 153.3, 148.1, 137.6, 130.3, 126.9, 124.2, 108.1, 52.3, 28.8, 12.7; IR (KBr) ν 3101, 2875, 1743, 1651, 1640, 1594, 1548, 1512, 1365, 1287, 1017, 893, 753, 648 cm^{-1} HRMS (APCI-TOF) calcd for $[\text{C}_{14}\text{H}_{13}\text{N}_3\text{O}_4 + \text{H}]^+$ 288.0979, found 288.0974.

2-Methyl-1-(3-(*m*-tolyl)-1*H*-pyrazol-1-yl)butane-1,3-dione (5ga). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 78 % yield (100 mg, 0.39 mmol); mp 56-57 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.28-8.27 (m, 1H), 7.63 (m, 2H), 7.33 (t, $J = 7.2$ Hz, 1H), 7.22 (m, 1H), 6.78 (m, 1H), 4.82 (q, $J = 7.2$ Hz, 1H), 2.42 (s, 3H), 2.40 (s, 3H), 1.52 (d, $J = 7.2$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 204.0, 169.1, 155.8, 138.5, 131.4, 130.1, 129.6, 128.7, 126.9, 123.4, 108.0, 52.2, 29.0, 21.4, 12.7; IR (KBr) ν 3198, 2959, 1864, 1672, 1652, 1589, 1552, 1348, 1209, 1109, 806, 766 cm^{-1} ; HRMS (APCI-TOF) calcd for $[\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_2 + \text{H}]^+$ 257.1285, found 257.1286.

2-Methyl-1-phenyl-3-(3-phenyl-1*H*-pyrazol-1-yl)propane-1,3-dione (5ab). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 81 % yield (123 mg, 0.40 mmol); mp 94-95 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.26 (d, $J = 3.0$ Hz, 1H), 8.10 (d, $J = 7.5$ Hz, 2H), 7.64 (t, $J = 7.5$ Hz, 1H), 7.56-7.48 (m, 4H), 7.29-7.26 (m, 4H), 6.75 (d, $J = 3.0$ Hz, 1H), 5.62 (q, $J = 6.9$ Hz, 1H), 1.63 (d, $J = 6.9$ Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 196.9, 169.4, 155.2, 135.6, 133.3, 131.4, 129.6, 129.1, 128.9, 128.8, 128.7, 128.6, 126.3, 126.1, 107.6, 47.3, 13.6; IR (KBr) ν 3198, 2844, 1867, 1778, 1762, 1654, 1625, 1568, 1451, 1411, 1245, 1067, 937, 826, 759 cm^{-1} ; HRMS (APCI-TOF) calcd for $[\text{C}_{19}\text{H}_{16}\text{N}_2\text{O}_2 + \text{H}]^+$ 305.1285, found 305.1282.

2-Methyl-1-phenyl-3-(3-(*p*-tolyl)-1*H*-pyrazol-1-yl)propane-1,3-dione (5bb). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 84 % yield (133 mg, 0.42 mmol); mp 129-130 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.26 (d, $J = 3.0$ Hz, 1H), 8.10 (d, $J = 7.5$ Hz, 2H), 7.64 (t, $J = 7.5$ Hz, 1H), 7.53 (t, $J = 7.5$ Hz, 2H), 7.38 (d, $J = 7.8$ Hz, 2H), 7.08 (d, $J = 7.8$ Hz, 2H), 6.71 (d, $J = 3.0$ Hz, 1H), 5.61 (q, $J = 7.2$ Hz, 1H), 2.33 (s, 3H), 1.62 (d, $J = 7.2$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 196.9, 169.4, 155.3, 139.2, 135.7, 133.3, 129.5, 129.3, 128.7, 128.6, 126.0, 109.9, 107.5, 47.3, 21.3, 13.6; IR (KBr) ν 3198, 2889, 1853, 1663, 1647, 1632, 1582, 1569, 1456, 1354, 1258, 1175, 947, 832 cm^{-1} ; HRMS (APCI-TOF) calcd for $[\text{C}_{20}\text{H}_{18}\text{N}_2\text{O}_2 + \text{H}]^+$ 319.1441, found 319.1445.

1-(3-(4-Methoxyphenyl)-1*H*-pyrazol-1-yl)-2-methyl-3-phenylpropane-1,3-dione (5cb). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (142 mg, 0.42 mmol); mp 117-118 °C; ^1H NMR (300 MHz, CDCl_3) δ

8.24 (d, $J = 2.7$ Hz, 1H), 8.09 (d, $J = 6.9$ Hz, 2H), 7.66-7.62 (m, 1H), 7.53 (t, $J = 7.5$ Hz, 2H), 7.43-7.41 (m, 2H), 6.79 (d, $J = 8.7$ Hz, 2H), 6.68 (d, $J = 2.7$ Hz, 1H), 5.60 (q, $J = 7.2$ Hz, 1H), 3.80 (s, 3H), 1.62 (d, $J = 7.2$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 197.0, 169.3, 160.4, 155.0, 135.7, 133.3, 129.5, 128.8, 128.7, 127.4, 124.1, 113.9, 107.3, 55.2, 47.3, 13.6; IR (KBr) ν 3121, 2812, 1818, 1651, 1629, 1569, 1524, 1479, 1345, 1289, 1161, 1023, 852, 739 cm^{-1} ; HRMS (APCI-TOF) calcd for $[\text{C}_{20}\text{H}_{18}\text{N}_2\text{O}_3 + \text{H}]^+$ 335.1390, found 335.1393.

1-(3-(4-Fluorophenyl)-1*H*-pyrazol-1-yl)-2-methyl-3-phenylpropane-1,3-dione (5kb**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 86 % yield (138 mg, 0.43 mmol); mp 118-119 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.27 (d, $J = 2.7$ Hz, 1H), 8.09 (d, $J = 7.2$ Hz, 2H), 7.65 (t, $J = 7.2$ Hz, 1H), 7.54 (t, $J = 7.8$ Hz, 2H), 7.46-7.41 (m, 2H), 6.94 (t, $J = 8.7$ Hz, 2H), 6.69 (d, $J = 2.7$ Hz, 1H), 5.58 (q, $J = 6.9$ Hz, 1H), 1.63 (d, $J = 6.9$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 196.9, 169.3, 163.2 (d, $^1J_{\text{C}-\text{F}} = 247.6$ Hz), 154.3, 135.6, 133.4, 129.7, 128.8 (d, $^3J_{\text{C}-\text{F}} = 9.1$ Hz), 128.6, 127.9 (d, $^4J_{\text{C}-\text{F}} = 8.2$ Hz), 127.6, 127.6, 115.6 (d, $^2J_{\text{C}-\text{F}} = 21.6$ Hz), 107.3, 47.3, 13.6; ^{19}F NMR (470 MHz, CDCl_3) δ -111.9; IR (KBr) ν 3118, 2891, 1854, 1703, 1682, 1642, 1582, 1526, 1452, 1352, 1265, 1174, 1083, 974, 674 cm^{-1} ; HRMS (APCI-TOF) calcd for $[\text{C}_{19}\text{H}_{15}\text{FN}_2\text{O}_2 + \text{H}]^+$ 323.1190, found 323.1194.

1-(3-(4-Chlorophenyl)-1*H*-pyrazol-1-yl)-2-methyl-3-phenylpropane-1,3-dione (5db**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 87 % yield (147 mg, 0.43 mmol); mp 148-149 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.28 (d, $J = 2.7$ Hz, 1H), 8.09 (d, $J = 7.2$ Hz, 2H), 7.66 (t, $J = 7.2$ Hz, 1H), 7.54 (d, $J = 7.2$ Hz, 2H), 7.39-7.36 (m, 2H), 7.24-7.21 (m, 2H), 6.70 (d, $J = 2.4$ Hz, 1H), 5.57 (q, $J = 7.2$ Hz, 1H), 1.63 (d, $J = 7.2$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 196.9, 169.3, 154.1, 135.5, 135.0, 133.4, 129.9, 129.8, 128.8, 128.8, 128.7, 127.3, 107.3, 47.3, 13.5; IR (KBr) ν 3127, 2874, 1832, 1683, 1661, 1630, 1576, 1529, 1459, 1431, 1380, 1254, 1127, 957, 769 cm^{-1} ; HRMS (APCI-TOF) calcd for $[\text{C}_{19}\text{H}_{15}\text{ClN}_2\text{O}_2 + \text{H}]^+$ 339.0895, found 339.0898.

2-Methyl-1-phenyl-3-(3-(4-(trifluoromethyl)phenyl)-1*H*-pyrazol-1-yl)propane-1,3-dione (5eb**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 87 % yield (147 mg, 0.43 mmol); mp 134-135 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.32 (d, $J = 2.7$ Hz, 1H), 8.10 (d, $J = 7.2$ Hz, 2H), 7.68 (t, $J = 7.2$ Hz, 1H), 7.58-7.48 (m, 6H), 6.78 (d, $J = 2.7$ Hz, 1H), 5.59 (q, $J = 6.9$ Hz, 1H), 1.64 (d, $J = 6.9$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 197.3, 169.7, 154.1, 135.8, 135.2, 133.9, 131.2 (q, $^2J_{\text{C}-\text{F}} = 32.3$ Hz), 130.3, 129.3, 129.1, 126.6, 129.5, 125.9, 124.3 (q, $^1J_{\text{C}-\text{F}} = 270.0$ Hz), 107.9, 47.7, 14.0; ^{19}F NMR (470 MHz, CDCl_3) δ -62.7; IR (KBr) ν 3197, 2866, 1896, 1759, 1650, 1645, 1601, 1530, 1526, 1456, 1357, 1203, 1187, 1086, 1034, 978, 854 cm^{-1} ; HRMS (APCI-TOF) calcd for $[\text{C}_{19}\text{H}_{15}\text{F}_3\text{N}_2\text{O}_2 + \text{H}]^+$ 373.1158, found 373.1154.

2-Methyl-1-(3-(4-nitrophenyl)-1*H*-pyrazol-1-yl)-3-phenylpropane-1,3-dione (5lb**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 88 % yield (153 mg, 0.44 mmol); mp 152-153 °C; ^1H NMR (300 MHz, CDCl_3) δ 8.34 (d, $J = 2.4$ Hz, 1H), 8.10 (d, $J = 7.8$ Hz, 4H), 7.73-7.69 (m, 1H), 7.60-7.55 (m, 4H), 6.81 (d, $J = 2.4$ Hz, 1H), 5.57 (q, $J = 6.9$ Hz, 1H), 1.65 (d, $J = 6.9$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 196.8, 169.2, 152.8, 147.9, 137.5, 135.3, 133.7, 130.2, 129.0, 128.7, 126.6, 123.9, 107.7, 47.3, 13.5; IR (KBr) ν 3131, 2894, 1857, 1710, 1658, 1641, 1526, 1453, 1394, 1203, 1187, 1031, 945, 794 cm^{-1} ; HRMS (APCI-TOF) calcd for $[\text{C}_{19}\text{H}_{15}\text{N}_3\text{O}_4 + \text{H}]^+$ 350.1135, found 350.1133.

1-(3-(2-Chlorophenyl)-1*H*-pyrazol-1-yl)-2-methyl-3-phenylpropane-1,3-dione (5ib). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 84 % yield (142 mg, 0.42 mmol); mp 78-79 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.30 (d, *J* = 2.7 Hz, 1H), 8.08 (d, *J* = 7.5 Hz, 2H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.50 (t, *J* = 7.5 Hz, 2H), 7.39 (d, *J* = 7.8 Hz, 1H), 7.31-7.21 (m, 2H), 7.07 (t, *J* = 7.5 Hz, 1H), 6.99 (d, *J* = 2.7 Hz, 1H), 5.63 (q, *J* = 6.9 Hz, 1H), 1.63 (d, *J* = 6.9 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 196.8, 169.4, 153.4, 135.4, 133.4, 132.6, 130.5, 130.4, 129.9, 128.8, 128.7, 126.7, 111.4, 47.3, 13.6; IR (KBr) ν 3187, 2895, 1867, 1698, 1607, 1590, 1548, 1460, 1440, 1349, 1187, 1015, 986, 795 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₉H₁₅ClN₂O₂ + H]⁺ 339.0895, found 339.0896.

1-(3-(2,4-Dimethylphenyl)-1*H*-pyrazol-1-yl)-2-methyl-3-phenylpropane-1,3-dione (5mb). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 85 % yield (142 mg, 0.42 mmol); mp 89-90 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.30 (d, *J* = 2.7 Hz, 1H), 8.04 (d, *J* = 7.5 Hz, 2H), 7.60 (t, *J* = 7.5 Hz, 1H), 7.48 (t, *J* = 7.5 Hz, 2H), 6.97-6.94 (m, 2H), 6.63 (d, *J* = 2.7 Hz, 1H), 5.63 (q, *J* = 7.2 Hz, 1H), 2.30 (s, 3H), 2.18 (s, 3H), 1.63 (d, *J* = 7.2 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 196.7, 169.6, 156.2, 138.6, 136.4, 135.2, 133.5, 131.9, 130.1, 129.3, 129.2, 129.0, 128.8, 126.5, 110.5, 47.3, 21.1, 21.1, 13.7; IR (KBr) ν 3176, 2876, 1868, 1766, 1684, 1630, 1583, 1564, 1461, 1243, 1086, 961, 746 cm⁻¹; HRMS (APCI-TOF) calcd for [C₂₁H₂₀N₂O₂ + H]⁺ 333.1598, found 333.1600.

2-Methyl-1-phenyl-3-(4,5,6,7-tetrahydro-2*H*-indazol-2-yl)propane-1,3-dione (8ab). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 81 % yield (115 mg, 0.41 mmol); mp 117-118 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.01 (d, *J* = 7.5 Hz, 2H), 7.91 (s, 1H), 7.57 (t, *J* = 7.2 Hz, 1H), 7.47 (t, *J* = 7.5 Hz, 2H), 5.57 (q, *J* = 7.2 Hz, 1H), 2.57 (m, 4H), 1.84-1.71 (m, 4H), 1.58-1.55 (m, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 196.9, 169.3, 155.4, 135.6, 133.2, 128.7, 124.7, 121.3, 47.0, 23.7, 22.8, 20.6, 13.8; IR (KBr) ν 3115, 2810, 1798, 1657, 1649, 1597, 1568, 1564, 1404, 1311, 1389, 1134, 943, 883 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₇H₁₈N₂O₂ + H]⁺ 283.1441, found 283.1445.

2-Methyl-1-phenyl-3-(1*H*-pyrazol-1-yl)propane-1,3-dione (8bb). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 83 % yield (95mg, 0.41 mmol); mp 117-118 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.27 (d, *J* = 8.4 Hz, 1H), 8.06-8.04 (m, 3H), 7.61-7.57 (m, 1H), 7.51-7.42 (m, 3H), 5.65 (q, *J* = 7.2 Hz, 1H), 2.57 (s, 3H), 1.65 (q, *J* = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 196.7, 169.6, 144.1, 135.2, 133.5, 128.8, 128.7, 128.5, 109.9, 47.4, 13.7; IR (KBr) ν 3176, 1766, 1671, 1664, 1508, 1464, 1243, 1177, 966, 746 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₃H₁₂N₂O₂ + H]⁺ 229.0972, found 229.0975.

2-Methyl-1-(4-methyl-1*H*-indazol-1-yl)-3-phenylpropane-1,3-dione (11ab). This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 87 % yield (127 mg, 0.43 mmol); mp 112-113°C; ¹H NMR (300MHz, CDCl₃) δ 8.27 (d, *J* = 8.4 Hz, 1H), 8.05 (t, *J* = 7.5 Hz, 3H), 7.59 (t, *J* = 7.5 Hz, 1H), 7.48-7.42 (m, 3H), 7.13 (d, *J* = 7.4 Hz, 1H), 5.65 (q, *J* = 7.2 Hz, 1H), 2.57 (s, 3H), 1.65 (d, *J* = 7.5 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 197.1, 170.8, 139.0, 135.5, 133.3, 131.5, 128.8, 128.7, 126.5, 125.0, 112.8, 48.2, 18.3, 13.8; IR (KBr) ν 3109, 2863, 1865, 1767, 1684, 1621, 1570, 1542, 1531, 1489, 1360, 1254, 1195, 1089, 876, 790 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₃H₁₄N₂O₂ + H]⁺ 293.1285, found 293.1290.

Characterization Data of Compounds 10aa-10ac

2,2-Dimethyl-5-(4-methyl-1*H*-indazole-1-carbonyl)cyclopentanone (10aa**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 78 % yield (105 mg, 0.39 mmol); mp 115-116 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.22 (m, 2H), 7.45 (t, *J* = 7.8 Hz, 1H), 7.15 (d, *J* = 7.2 Hz, 1H), 4.91-4.85 (m, 1H), 2.61 (s, 3H), 2.51-2.40 (m, 2H), 2.32-2.21 (m, 2H), 1.30 (s, 3H), 1.18 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 212.2, 169.9, 139.2, 139.0, 131.5, 129.7, 126.6, 125.2, 113.0, 54.3, 53.3, 41.3, 34.8, 29.2, 27.9, 18.3; IR (KBr) ν 3176, 2859, 1860, 1785, 1600, 1564, 1516, 1471, 1354, 1258, 1134, 1041, 923, 827 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₈H₁₈N₂O₂ + H]⁺ 271.1441, found 271.1444.

2-Methyl-5-(4-methyl-1*H*-indazole-1-carbonyl)cyclopentanone (10ab**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 77 % yield (98 mg, 0.38 mmol); mp 115-116 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.26-8.18 (m, 2H), 7.45 (t, *J* = 7.8 Hz, 1H), 7.15 (d, *J* = 7.2 Hz, 1H), 4.85-4.70 (m, 1H), 2.71-2.50 (m, 5H), 2.37-2.07 (m, 3H), 1.26-1.18 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 211.9, 169.6, 139.1, 139.0, 131.5, 129.7, 126.6, 125.1, 113.0, 56.5, 52.9, 46.8, 46.7, 35.9, 35.2, 30.0, 29.0, 20.7, 19.9, 18.3; IR (KBr) ν 3110, 2812, 1842, 1678, 1666, 1580, 1539, 1501, 1458, 1346, 1258, 1134, 1082, 847, 796 cm⁻¹; HRMS (APCI-TOF) calcd for [C₁₅H₁₆N₂O₂ + H]⁺ 257.1285, found 257.1281.

2-(4-methyl-1*H*-indazole-1-carbonyl)-5-phenylcyclopentanone (10ac**).** This compound was purified by column chromatography (ethyl acetate/petroleum ether = 1:8) to afford a white solid in 84 % yield (133 mg, 0.42 mmol); mp 115-116 °C; ¹H NMR (300 MHz, CDCl₃) δ 8.27-8.22 (m, 2H), 7.47 (t, *J* = 7.8 Hz, 1H), 7.37-7.29 (m, 5H), 7.16 (d, *J* = 6.9 Hz, 1H), 4.96-4.78 (m, 1H), 3.59-3.46 (m, 1H), 3.00-2.69 (m, 3H), 2.62 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 210.5, 169.3, 152.4, 143.0, 141.9, 139.4, 139.4, 139.0, 131.6, 129.8, 128.8, 127.0, 126.9, 126.7, 126.6, 125.3, 113.0, 112.9, 56.6, 53.2, 46.0, 45.6, 40.4, 39.6, 35.6, 35.4, 18.3; IR (KBr) ν 3129, 2872, 1865, 1762, 1640, 1594, 1588, 1456, 1371, 1360, 1265, 1074, 985, 693 cm⁻¹; HRMS (APCI-TOF) calcd for [C₂₀H₁₈N₂O₂ + H]⁺ 319.1441, found 319.1444.

X-Ray Crystallography structures of Compound **3nc**, **5cb** and **10ac**




Figure S1. X-ray crystal structure of **3nc**

Crystal data for **3nc**: $C_{21}H_{16}BrN_2O_2$, Mr = 408.26, Orthorhombic, $a = 11.3784(10)$ Å, $b = 8.5648(7)$ Å, $c = 37.271(3)$ Å, $\alpha = 90^\circ$, $\beta = 90^\circ$, $\gamma = 90^\circ$, $V = 3632.2(5)$ Å³, $T = 293$ (2) K, space group Pbc₁, Z = 8, 34343 reflections collected, 3336 unique (Rint = 0.0666) which were used in all calculation. The ellipsoid contour probability level in the caption of 30 %. Crystallographic data for compound **3nc** reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. **CCDC-1919855**.




Figure S2. X-ray crystal structure of **5cb**

Crystal data for **5cb**: $C_{20}H_{18}N_2O_3$, Mr = 334.36, Orthorhombic, $a = 10.0547(13)$ Å, $b = 19.198(3)$ Å, $c = 8.7595(13)$ Å, $\alpha = 90^\circ$, $\beta = 90^\circ$, $\gamma = 90^\circ$, $V = 1690.8(4)$ Å³, $T = 293$ (2) K, space group Pna₂₁, Z = 4, 10996 reflections collected, 3330 unique (R(int) = 0.0727) which were used in all calculation. The ellipsoid contour probability level in the caption of 30 %. Crystallographic data for compound **5cb** reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. **CCDC-1919853**.







Figure S3. X-ray crystal structure of **10ac**

Crystal data for **10ac**: $C_{20}H_{18}N_2O_2$, Mr = 318.36, Monoclinic, $a = 6.8253(4)$ Å, $b = 7.8483(4)$ Å, $c = 30.9897(18)$ Å, $\alpha = 90^\circ$, $\beta = 97.986(2)^\circ$, $\gamma = 90^\circ$, $V = 1690.8(4)$ Å³, $T = 293$ (2) K, space group P2₁/c, Z = 4, 32327 reflections collected, 2988 unique (R(int) = 0.0260) which were used in all calculation. The ellipsoid contour probability level in the caption of 30 %. Crystallographic data for compound **5cb** reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. **CCDC-1919853**.




¹H NMR and ¹³C NMR Spectra of Compound 3aa




¹H NMR and ¹³C NMR Spectra of Compound 3ba




¹H NMR and ¹³C NMR Spectra of Compound 3ca




¹H NMR and ¹³C NMR Spectra of Compound 3da




¹H NMR, ¹⁹F NMR and ¹³C NMR Spectra of Compound 3ea








¹H NMR and ¹³C NMR Spectra of Compound 3fa




¹H NMR and ¹³C NMR Spectra of Compound 3ga




¹H NMR and ¹³C NMR Spectra of Compound 3ha




¹H NMR and ¹³C NMR Spectra of Compound 3ia




¹H NMR and ¹³C NMR Spectra of Compound 3ab




¹H NMR and ¹³C NMR Spectra of Compound 3cb




¹H NMR, ¹⁹F NMR and ¹³C NMR Spectra of Compound 3kb








¹H NMR and ¹³C NMR Spectra of Compound 3db




¹H NMR and ¹³C NMR Spectra of Compound 3hb




¹H NMR and ¹³C NMR Spectra of Compound 3mb




¹H NMR and ¹³C NMR Spectra of Compound 3ac




¹H NMR and ¹³C NMR Spectra of Compound 3bc




¹H NMR and ¹³C NMR Spectra of Compound 3cc




¹H NMR and ¹³C NMR Spectra of Compound 3dc





¹H NMR and ¹³C NMR Spectra of Compound 3nc




¹H NMR and ¹³C NMR Spectra of Compound 3fc




¹H NMR and ¹³C NMR Spectra of Compound 3hc





¹H NMR and ¹³C NMR Spectra of Compound 3ic




¹H NMR and ¹³C NMR Spectra of Compound 3bd




¹H NMR, ¹⁹F NMR ¹³C NMR Spectra of Compound 3kd




-112.732







¹H NMR and ¹³C NMR Spectra of Compound 3nd




¹H NMR and ¹³C NMR Spectra of Compound 3gd




¹H NMR and ¹³C NMR Spectra of Compound 3md




¹H NMR and ¹³C NMR Spectra of Compound 3be




¹H NMR and ¹³C NMR Spectra of Compound 3ce




¹H NMR, ¹⁹F NMR and ¹³C NMR Spectra of Compound 3ke







¹H NMR and ¹³C NMR Spectra of Compound 3ne





¹H NMR and ¹³C NMR Spectra of Compound 3me




¹H NMR and ¹³C NMR Spectra of Compound 5aa





¹H NMR and ¹³C NMR Spectra of Compound 5ba




¹H NMR and ¹³C NMR Spectra of Compound 5fa




¹H NMR and ¹³C NMR Spectra of Compound 5na





¹H NMR, ¹⁹F NMR and ¹³C NMR Spectra of Compound 5ea







¹H NMR and ¹³C NMR Spectra of Compound 5la




¹H NMR and ¹³C NMR Spectra of Compound 5ga




¹H NMR and ¹³C NMR Spectra of Compound 5ab




¹H NMR and ¹³C NMR Spectra of Compound 5bb




¹H NMR and ¹³C NMR Spectra of Compound 5cb




¹H NMR and ¹³C NMR Spectra of Compound 5kb







¹H NMR and ¹³C NMR Spectra of Compound 5db




¹H NMR, ¹⁹F NMR and ¹³C NMR Spectra of Compound 5eb







¹H NMR and ¹³C NMR Spectra of Compound 5lb




¹H NMR and ¹³C NMR Spectra of Compound 5ib




¹H NMR and ¹³C NMR Spectra of Compound 5mb




¹H NMR and ¹³C NMR Spectra of Compound 7aa




¹H NMR and ¹³C NMR Spectra of Compound 7ab




¹H NMR and ¹³C NMR Spectra of Compound 7ac




¹H NMR and ¹³C NMR Spectra of Compound 8ab




¹H NMR and ¹³C NMR Spectra of Compound 8bb





¹H NMR and ¹³C NMR Spectra of Compound 10aa



¹H NMR and ¹³C NMR Spectra of Compound 10ab





¹H NMR and ¹³C NMR Spectra of Compound 11ab

